NCT00621270已完成2 期
A 6-Week Randomised Double-Blind, Placebo-Controlled Study of BCI-540 80 mg q.d. and 80 mg t.i.d. in the Treatment of Adults With Major Depressive Disorder and Concomitant Anxiety
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 115
- 试验地点
- 16
- 主要终点
- Co-primary outcome measures will be the change from Baseline to Week 6 on the total score of the Inventory of Depressive Symptomatology-Clinician Version (IDS-C30) and the Hamilton Rating Scale for Anxiety (HAM-A).
研究概览
简要总结
The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.
详细描述
BCI-540 has been shown to be neurogenic in the Sponsor's in vitro neural stem cell analyses and in vivo animal models of depression and anxiety. These observations and the recent findings linking hippocampal function and neurogenesis to mood disorders support the evaluation of the efficacy, safety, and tolerability of BCI-540 in patients with major depressive disorder with concomitant anxiety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient meets the DSM IV-TR criteria for Major Depressive Disorder (MDD) as determined by the Mini-International Neuropsychiatric Interview (MINI) and psychiatric evaluation.
- •The patient has a score of 20 or more on the HAM D17 scale, a score of 30 or more on the IDS-C30 and a score of 15 or more on the HAM-A scale at the Screening and Baseline visits.
- •The patient has a score of at least 2 on items 1 and 2 of the HAM-A scale at the Screening and Baseline visits.
- •The patient has a Clinical Global Impression of Severity (CGI S) rating of 4 or higher at the Screening and Baseline visits.
- •The patient has recurrent MDD.
- •The patient did not respond to at least one but no more than five adequate antidepressant trials during the current MDD episode.
- •The patient is living with another adult or has daily contact with an adult and contact information for the patient and this adult is available to the investigator.
- •Female patients of childbearing potential must be using a reliable, medically acceptable form of contraception for at least 30 days prior to the screening visit and must agree to continue such use throughout the duration of the study and for 30 days after the final dose of study drug.
排除标准
- •The patient has a decrease of 20% or more in HAM D17 total score or HAM-A total score from the screening visit to the Baseline visit.
- •The patient represents significant risk of suicide in the opinion of the investigator at the screening or Baseline visit.
- •The patient has any other psychiatric Axis-I disorder (except GAD) as a principal diagnosis within 6 months of Screening.
- •The patient has a history of obsessive compulsive disorder, psychotic disorder, bipolar disorder, mental retardation.
- •The patient has a history of alcohol or substance (excluding nicotine or caffeine) abuse within 3 months of the screening visit, alcohol or substance dependence within 6 months of Screening.
- •The patient shows current evidence of substance abuse confirmed by results of a urine drug screen.
- •The patient has used an antidepressant medication (SSRI/SNRI or any other antidepressant medication, including MAOIs), within 1 week of Baseline(fluoxetine within 5 weeks).
- •The patient has a history of low RBC count, low hemoglobin, low WBC count, low platelets, or low reticulocyte counts of any aetiology other than that known to be related to blood loss, iron deficiency, or pregnancy.
- •The patient shows current evidence of macrocytosis, low RBC count, low haemoglobin, low WBC count, or low platelet count of any aetiology.
- •The patient will use drugs during the study (including follow-up) that are known to be related to agranulocytosis and/or aplastic anaemia.
- •The patient will receive interpersonal therapy and/or short-term (brief) dynamic therapy during the study.
- •The patient received ECT within 3 months of Screening.
- •The patient received depot antipsychotic therapy at any time.
- •The patient has used any antipsychotic or anxiolytic medications within 1 week of Screening.
- •The patient has used any drugs with known psychotropic properties or any non-psychotropic drugs with potential CNS effects within one week or 5-half lives (whichever is longer) of Screening.
- •The patient has a clinically significant cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurological, malignancy, metabolic, psychiatric or other condition that might be detrimental to the patient if he or she participates in the study.
- •The patient has a known hypersensitivity to any cholinesterase inhibitors or cholinergic agonist drugs.
- •The patient is a pregnant or lactating woman.
- •The patient has a history of seizures.
- •The patient has clinically significant abnormalities on screening physical examination, ECG, serum chemistry, urinalysis tests, including thyroid stimulating hormone levels, as judged by the investigator.
- •The patient has a known positivity for human immunodeficiency virus, hepatitis B surface-antigen, or hepatitis C virus antibody.
研究组 & 干预措施
1
Experimental
BCI-540 80 mg once a day (q.d.)
干预措施: BCI-540 (Drug)
2
Experimental
BCI-540 80 mg three times a day (t.i.d.)
干预措施: BCI-540 (Drug)
3
Placebo Comparator
Placebo
干预措施: BCI-540 (Drug)
结局指标
主要结局
Co-primary outcome measures will be the change from Baseline to Week 6 on the total score of the Inventory of Depressive Symptomatology-Clinician Version (IDS-C30) and the Hamilton Rating Scale for Anxiety (HAM-A).
时间窗: Week 6
次要结局
- The safety, tolerability and side effect profile of BCI-540 will also be measured by adverse events, clinical laboratory values, electrocardiograms, vital signs, and the Physician Withdrawal Checklist (PWC).(Weeks 2, 4, 6, 7 and 12)
研究者
研究点 (16)
Loading locations...
相似试验
终止
2 期
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)AsthmaNCT01397201Boehringer Ingelheim30
终止
2 期
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) TherapyAsthmaNCT01397162Boehringer Ingelheim29
已完成
3 期
Study Evaluating Bifeprunox in Bipolar DepressionDepression BipolarNCT00245973Wyeth is now a wholly owned subsidiary of Pfizer380
已完成
3 期
Study Evaluating Bifeprunox in Bipolar DepressionBipolar DisorderNCT00134459Wyeth is now a wholly owned subsidiary of Pfizer434
已完成
1 期
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgParkinson DiseaseNCT03097211Bial - Portela C S.A.38